210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd

Key Points

• CIBRA Capital Ltd bought a new stake of 210,800 shares (~$3.00M) in Amicus Therapeutics (NASDAQ: FOLD) in Q4, representing 5.2% of CIBRA's holdings and about 0.07% of Amicus outstanding, making it CIBRA's 11th largest position.
• Amicus reported quarterly revenue of $185.21M (up 23.7% YoY) but missed EPS at $0.10 versus a $0.13 consensus; the company has a market cap of $4.52B and a one‑year trading range of $5.51–$14.43.
• CEO Bradley Campbell sold 75,000 shares at an average of $14.31 (a 6.84% reduction in his stake), while analysts show a mixed outlook with a consensus rating of Hold and a $15.39 price target.

CIBRA Capital Ltd bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 210,800 shares of the biopharmaceutical company's stock, valued at approximately $3,002,000. Amicus Therapeutics comprises 5.2% of CIBRA Capital Ltd's holdings, making the stock its 11th largest holding. CIBRA Capital Ltd owned about 0.07% of Amicus Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Ion Asset Management Ltd. purchased a new stake in Amicus Therapeutics during the third quarter valued at $6,875,000. Norges Bank purchased a new position in Amicus Therapeutics in the second quarter worth about $18,540,000. Jump Financial LLC boosted its position in Amicus Therapeutics by 246.3% in the second quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company's stock worth $8,060,000 after purchasing an additional 1,000,395 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $2,961,000. Finally, Nordea Investment Management AB bought a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $7,843,000.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $14.41 on Friday. The company has a market capitalization of $4.52 billion, a P/E ratio of -180.13 and a beta of 0.43. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $14.43. The firm's 50 day simple moving average is $14.34 and its two-hundred day simple moving average is $11.63. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The firm had revenue of $185.21 million for the quarter, compared to the consensus estimate of $185.00 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. The firm's revenue for the quarter was up 23.7% on a year-over-year basis. Research analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 75,000 shares of the business's stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total value of $1,073,250.00. Following the transaction, the chief executive officer directly owned 1,021,180 shares in the company, valued at $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on FOLD. Guggenheim cut shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Leerink Partners cut shares of Amicus Therapeutics from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $17.00 to $14.50 in a report on Monday, December 29th. Needham & Company LLC downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 19th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Amicus Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $15.39.

About Amicus Therapeutics

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.